INM (InMed Pharmaceuticals Inc.) חוב לטווח קצר להון

InMed Pharmaceuticals (INM) is a leading developer in the genetic synthesis of rare cannabinoids for skin and eye therapies. The company's revenues rely on the supply of specialized agents to clinics for the treatment of complex pathologies. As reflected in the pakistan chart, the asset value is 0.00. Growth prospects are tied to the completion of clinical trials for new dermatological products in a high-demand segment.

To minimize credit risks, it is essential for investors to monitor the ratio of short-term liabilities to equity, which allows for an assessment of the issuer's ability to settle loans under one year using its own assets; by analyzing the historical share of short-term debt in equity, one can determine whether the debt load restricts InMed Pharmaceuticals (INM) from funding advanced R&D and the work of chemical technologists on the synthesis of rare cannabinoids.